E
C
U
AT
ER
IA
L
-D
AL
T
ER
O
R
EP
R
O
D
PY
R
IG
H
E
C
U
EXECUTIVE SUMMARY
EP
R
O
D
uPDateD 2009
PY
R
IG
H
TE
D
AT
ER
IA
L
-D
AL
T
ER
O
R
C
U
O
D
A. G. Agusti, MD
Hospital University Son Dureta
Palma de Mallorca, Spain
Peter Calverley, MD
University Hospital Aintree
Liverpool, England, UK
Jean Bourbeau, MD
McGill University Health Centre
Montreal, Quebec, Canada
EP
R
Peter Calverley, MD
University Hospital Aintree
Liverpool, England, UK
O
R
Antonio Anzueto, MD
University of Texas Health Science Center
San Antonio, Texas, USA
ER
Teresita S. deGuia, MD
Philippine Heart Center
Quezon City, Philippines
AL
T
Peter J. Barnes, MD
National Heart and Lung Institute
London, England, UK
Yoshinosuke Fukuchi, MD
(Representing Asian Pacific Society for Respirology)
Tokyo, Japan
Marc Decramer, MD
University Hospitals
Leuven, Belgium
Leonardo M. Fabbri, MD
University of Modena&ReggioEmilia
Modena, Italy
Yoshinosuke Fukuchi, MD
Tokyo, Japan
IA
L
Paul Jones, MD
St George's Hospital Medical School
London, England, UK
AT
ER
Ali Kocabas, MD
Cukurova University School of Medicine
Adana, Turkey
-D
Christine Jenkins, MD
Woolcock Institute of Medical Research
Sydney NSW, Australia
Fernando Martinez, MD
University of Michigan School of Medicine
Ann Arbor, Michigan, USA
TE
D
Fernando Martinez, MD
University of Michigan School of Medicine
Ann Arbor, Michigan, USA
Roberto Rodriguez-Roisin, MD
University of Barcelona
Barcelona, Spain
IG
H
PY
R
Donald Sin, MD
St Paul's Hospital
Vancouver, Canada
Jorgen Vestbo, MD
Hvidovre University Hospital, Hvidore, Denmark
and University of Manchester
Manchester, UK
Jadwiga A. Wedzicha, MD
University College London
London, England, UK
Observers:
Mark Woodhead, MD
(Representing European Respiratory Society)
Manchester Royal Infirmary
Manchester England, UK
ii
executive summary: GLOBaL strateGy FOr tHe DiaGNOsis, maNaGemeNt aND PreveNtiON OF cOPD
TABLE OF CONTENTS
O
D
Preface .............................................................................................................................................vii
EP
R
Introduction ....................................................................................................................................viii
Methodology and Summary of New Recommendations .......................................................viii
Levels of Evidence ..................................................................................................................ix
ER
O
R
AL
T
-D
AT
ER
IA
L
TE
D
PY
R
IG
H
References ......................................................................................................................................22
iii
O
D
O
R
ER
AL
T
IA
L
-D
EP
R
AT
ER
IG
H
TE
D
PY
R
The Global Strategy for Diagnosis, Management and Prevention of COPD (updated 2009), the Executive Summary (updated 2009), the Pocket
Guide (updated 2009) and the complete list of references examined by the Committee are available on the GOLD website www.goldcopd.org.
Members (2008-2009): J. Vestbo, Chair; A. Agusti, A. Anzueto, P. Barnes, P. Calverley, M. Decramer, L. Fabbri, Y. Fukuchi, P. Jones, F. Martinez, K.
Rabe, R. Rodriguez-Roisin, D. Sin, J. Wedzicha.
iv
O
D
EP
R
AL
T
ER
O
R
AT
ER
IA
L
-D
Page 10, right column paragraph 3, delete second sentence and insert: Most studies have indicated that the
existing medications for COPD do not modify the longterm decline in lung function that is the hallmark of this
disease51, 95-97 (evidence a), although there is limited evidence that regular treatment with long-acting 2-agonists,
inhaled glucocorticosteriods, and its combination can
decrease the rate of decline of lung function289 (evidence
b). Therefore, pharmacotherapy for COPD is mainly used
to decrease symptoms and/or complications.
Reference 289: Celli BR, Thomas NE, Anderson JA,
Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K,
Yates JC, Calverley PM. Effect of pharmacotherapy on
rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J
Respir Crit Care Med. 2008 Aug 15;178(4):332-8. Epub
2008 May 29.
TE
D
IG
H
PY
R
O
D
EP
R
Page 12, Figure 8: Insert solution for nebulized formoterol 0.01 (mg/ml) and footnote: Formoterol nebulized solution is based on the unit dose vial containing 20
gm in a volume of 2.0ml
ER
O
R
T
O
N
IA
L
-D
AL
T
Stages of severity.
The role of simple spirometric criteria, symptoms and medical history for COPD diagnosis
TE
D
AT
ER
PY
R
IG
H
In preparation of the revised document, grading of evidence will continue to use four categories as described
on page xi. GOLD has been developing a system to utilize GRADE technology to identify key recommendations
that require more in-depth evaluation, and to implement
the creation and evaluation of evidence tables. This was
evaluated for the 2009 update by the use of GRADE
evaluation of a few predefined questions. More work on
this project will continue as the revised document is prepared based on these experiences.
vi
preface
EP
R
O
D
AL
T
ER
IA
L
-D
O
R
TE
D
AT
ER
PY
R
IG
H
vii
INTRODUCTION
EP
R
O
D
AL
T
ER
O
R
IA
L
-D
AT
ER
TE
D
IG
H
PY
R
viii
viii
O
D
O
R
EP
R
ER
LEVELS OF EVIDENCE
AL
T
-D
IG
H
TE
D
Randomized controlled
Evidence is from endpoints of well-designed RCTs that provide a
trials (RCTs). Rich body of data. consistent pattern of findings in the population for which the
recommendation is made. Category A requires substantial numbers
of studies involving substantial numbers of participants.
PY
R
O
Definition
Sources of Evidence
AT
ER
Evidence
Category
IA
L
Nonrandomized trials.
Observational studies.
ixix
1. DEFINITION, CLASSIFICATION OF
SEVERITY, AND MECHANISMS OF COPD
O
D
EP
R
O
R
ER
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; respiratory
failure: arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg)
with or without arterial partial pressure of CO2 (PaCO2) greater than 6.7 kPa
(50 mm Hg) while breathing air at sea level.
AL
T
-D
Stage I: Mild
DEFINITION
AT
ER
IA
L
IG
H
TE
D
PY
R
O
D
EP
R
O
R
ER
AL
T
2. BURDEN OF COPD
-D
AT
ER
IA
L
EPIDEMIOLOGY
TE
D
PY
R
IG
H
RISK FACTORS
O
D
EP
R
O
R
AL
T
ER
cigarette smoke
-D
IA
L
AT
ER
TE
D
PY
R
IG
H
Inhalational Exposures
Tobacco Smoke: Cigarette smokers have a higher
prevalence of respiratory symptoms and lung function
abnormalities, a greater annual rate of decline in FEV1,
and a greater COPD mortality rate than nonsmokers.
INTRODUCTION
AL
T
-D
O
R
Relieve symptoms
Prevent disease progression
Improve exercise tolerance
Improve health status
Prevent and treat complications
Prevent and treat exacerbations
Reduce mortality
ER
EP
R
O
D
IA
L
AT
ER
IG
H
TE
D
PY
R
O
D
IA
L
AT
ER
EP
R
O
R
ER
TE
D
IG
H
PY
R
AL
T
-D
KEY POINTS
INITIAL DIAGNOSIS
history of
exposure to
risk factors,
especially:
Tobacco smoke
Occupational dusts and chemicals
Smoke from home cooking and
heating fuels.
EP
R
O
D
ER
AL
T
O
N
AT
ER
IA
L
-D
O
R
IG
H
TE
D
PY
R
Asthma
Onset in mid-life.
Symptoms slowly progressive.
Long history of tobacco smoking.
Dyspnea during exercise.
Largely irreversible airflow limitation.
O
D
COPD
EP
R
suggestive features
diagnosis
ER
IA
L
AT
ER
Diffuse Panbronchiolitis
-D
Tuberculosis
AL
T
Bronchiectasis
O
R
IG
H
TE
D
PY
R
O
D
EP
R
O
R
ER
AL
T
AT
ER
-D
IA
L
PY
R
IG
H
TE
D
O
D
OCCUPATIONAL EXPOSURES
KEY POINTS
AL
T
ER
O
R
Regular treatment with long-acting bronchodilators is more effective and convenient than
treatment with short-acting bronchodilators
(Evidence A).
IG
H
TE
D
AT
ER
IA
L
-D
EP
R
PY
R
O
D
EP
R
O
R
ER
AL
T
PHARMACOLOGIC TREATMENTS
Pharmacologic therapy is used to prevent and control
symptoms (Figure 7), reduce the frequency and severity
of exacerbations, improve health status, and improve
exercise tolerance. Most studies have indicated that the
existing medications for COPD do not modify the longterm decline in lung function that is the hallmark of this
disease51, 95-97 (Evidence A), although there is limited evidence that regular treatment with long-acting 2-agonists, inhaled glucocorticosteriods, and its combination
can decrease the rate of decline of lung function289
(Evidence B). Therefore, pharmacotherapy for COPD is
mainly used to decrease symptoms and/or complications.
Bronchodilators: Bronchodilator medications are
central to the symptomatic management of COPD98-101
(Evidence A) (Figure 9). They are given either on an
as-needed basis for relief of persistent or worsening
symptoms, or on a regular basis to prevent or reduce
symptoms. The side effects of bronchodilator therapy
are pharmacologically predictable and dose dependent.
Adverse effects are less likely, and resolve more rapidly
after treatment withdrawal, with inhaled than with oral
treatment. When treatment is given by the inhaled route,
attention to effective drug delivery and training in inhaler
technique is essential.
IG
H
EDUCATION
TE
D
AT
ER
IA
L
-D
INTRODUCTION
PY
R
10
E
C
O
D
EP
R
iii: severe
ii: moderate
O
R
i: mild
ER
AL
T
-D
AT
ER
IA
L
chronic respiratory
failure
Consider surgical
treatments
PY
R
IG
H
TE
D
11
Inhaler
(g)
Solution for
Nebulizer (mg/ml)
Oral
0.5% (Syrup)
Duration of Action
(hours)
100-200 (MDI)
4-6
Salbutamol (albuterol)
Terbutaline
0.01*
4-6
0.1, 0.5
0.2, 0.25
Long-acting
Formoterol
0.0075
Salmeterol
Arformoterol
25-50 (MDI & DPI)
0.25-0.5
Oxitropium bromide
100 (MDI)
1.5
ER
20, 40 (MDI)
O
R
Anticholinergics
Short-acting
Ipratropium bromide
4-6
4-6
18 (DPI), 5 (SMI)
12+
12+
12+
6-8
7-9
AL
T
Long-acting
Tiotropium
O
D
0.21, 0.42
EP
R
Levalbuterol
Fenoterol
2-agonists
Short-acting
24+
1.25/0.5
75/15 (MDI)
0.75/4.5
Methylxanthines
Aminophylline
-D
Theophylline (SR)
Fluticasone
AT
ER
Budesonide
Triamcinolone
6-8
100 (MDI)
200-600 mg (Pill)
240
100-600 mg (Pill)
Variable, up to 24
Variable, up to 24
0.2-0.4
IA
L
Inhaled glucocorticosteroids
Beclomethasone
6-8
200/80 (MDI)
Salbutamol/Ipratropium
Fenoterol/Ipratropium
40
TE
D
Formoterol/Budesonide
Salmeterol/Fluticasone
Prednisone
IG
H
Systemic glucocorticosteroids
5-60 mg (Pill)
4, 8, 16 mg (Pill)
PY
R
Methyl-prednisolone
*Formoterol nebulized solution is based on the unit dose vial containing 20 gm in a volume of 2.0ml
12
EP
R
O
D
O
R
AL
T
AT
ER
IA
L
-D
ER
TE
D
PY
R
IG
H
An inhaled glucocorticosteroid combined with a longacting 2-agonist is more effective than the individual
components in reducing exacerbations and improving lung
function and health status123,125,126,130,131,271,272 (Evidence A).
Combination therapy increases the likelihood of pneumonia
and a large prospective clinical trial failed to demonstrate
statistically significant effects on mortality271, although in
patients with an FEV1 less than 60%, pharmacotherapy
with long-acting 2-agonist, inhaled glucocorticosteroid
and its combination decreased the rate of decline of lung
function289.
Antioxidant agents. Antioxidants, in particular N-acetylcysteine, have been reported in small studies to reduce
the frequency of exacerbations, leading to speculation
that these medications could have a role in the treatment
of patients with recurrent exacerbations155-158 (Evidence B).
13
EP
R
O
D
O
R
AL
T
-D
ER
TE
D
AT
ER
IA
L
IG
H
PY
R
NON-PHARMACOLOGIC TREATMENTS
14
O
D
O
R
ER
SPECIAL CONSIDERATIONS
AL
T
-D
Surgical Treatments
EP
R
AT
ER
IA
L
PY
R
IG
H
TE
D
15
O
D
EP
R
O
R
ER
IA
L
AT
ER
IG
H
INTRODUCTION
TE
D
AL
T
-D
PY
R
16
O
D
EP
R
O
R
HOME MANAGEMENT
AL
T
ER
-D
IA
L
PY
R
IG
H
TE
D
AT
ER
HOSPITAL MANAGEMENT
17
EP
R
O
D
AL
T
ER
-D
O
R
At all times:
Monitor fluid balance and nutrition
Consider subcutaneous heparin
IA
L
AT
ER
TE
D
IG
H
PY
R
18
EP
R
O
D
AL
T
ER
O
R
-D
AT
ER
IA
L
TE
D
selection criteria
Moderate to severe dyspnea with use of accessory
muscles and paradoxical abdominal motion
Moderate to severe acidosis (pH 7.35) and/ or
hypercapnia (PaCO2 > 6.0 kPa, 45 mm Hg)251
Respiratory frequency > 25 breaths per minute
IG
H
PY
R
19
O
D
EP
R
O
R
ER
AL
T
O
N
IA
L
-D
TE
D
AT
ER
PY
R
IG
H
20
AL
T
ER
O
R
EP
R
O
D
O
-D
KEY POINTS
Measurement of FEV1
4. TRANSLATING GUIDELINE
RECOMMENDATIONS TO THE
CONTEXT OF (PRIMARY) CARE
IA
L
TE
D
AT
ER
IG
H
DIAGNOSIS
PY
R
21
EP
R
O
D
A systematic review and meta-analysis of the effectiveness of integrated disease management programs for
care of patients with COPD concluded that these programs modestly improved exercise capacity, health-related quality of life, and hospital admissions267, 294 but there is
no effect on mortality294. Combining general practitioners
with practice nurses in one model had a positive effect on
patient compliance283. An integrated care intervention
including education, coordination among levels of care,
and improved accessibility, reduced hospital readmissions in chronic obstructive pulmonary disease (COPD)
after 1 year284.
O
R
ER
AL
T
IA
L
-D
COMORBIDITIES
AT
ER
IG
H
TE
D
PY
R
22
6.
-D
11.
AT
ER
26.
27.
PY
R
12.
25.
TE
D
10.
24.
IG
H
9.
13.
14.
22.
23.
IA
L
8.
EP
R
O
D
21.
O
R
20.
7.
19.
ER
5.
18.
AL
T
4.
17.
3.
16.
2.
1.
15.
REFERENCES
28.
29.
23
36.
40.
AT
ER
53.
54.
55.
PY
R
41.
42.
43.
51.
52.
TE
D
39.
EP
R
O
D
50.
IG
H
38.
O
R
49.
ER
48.
IA
L
37.
47.
AL
T
35.
Smith KR, Mehta S, Maeusezahl-Feuz M. Indoor airpollution from household solid fuel use. In: Ezzati M.,
Lopez, AD, Rodgers M., Murray CJ, eds. Comparative
quantification of health risks: global and regional burden
of disease attributable to selected major risk factors.
Geneva: World Health Organization; 2004.
Mishra V, Dai X, Smith KR, Mika L. Maternal exposure to
biomass smoke and reduced birth weight in Zimbabwe.
Ann Epidemiol 2004;14(10):740-7.
Boman C, Forsberg B, Sandstrom T. Shedding new light
on wood smoke: a risk factor for respiratory health.
Eur Respir J 2006;27(3):446-7.
Oroczo-Levi M, Garcia -Aymerich J, Villar J, RamirezSarmiento A, Anto JM, Gea J. Wood smoke exposure
and risk of chronic obstructive pulmonary disease.
Eur Respir J 2006;27:542-6.
Sezer H, Akkurt I, Guler N, Marakoglu K, Berk S. A
case-control study on the effect of exposure to different
substances on the development of COPD. Ann Epidemiol
2006;16(1):59-62.
Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC.
Chronic obstructive pulmonary disease surveillance
United States, 1971-2000. MMWR Surveill Summ
2002;51(6):1-16.
Xu X, Weiss ST, Rijcken B, Schouten JP. Smoking,
changes in smoking habits, and rate of decline in FEV1:
new insight into gender differences. Eur Respir J
1994;7(6):1056-61.
Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey
WC, Buist AS, et al. Effects of smoking intervention and
the use of an inhaled anticholinergic bronchodilator on
the rate of decline of FEV1. The Lung Health Study.
JAMA 1994;272(19):1497-505.
Silverman EK, Weiss ST, Drazen JM, Chapman HA,
Carey V, Campbell EJ, et al. Gender-related differences
in severe, early-onset chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2000;162(6):2152-8.
Tager IB, Segal MR, Speizer FE, Weiss ST. The natural
history of forced expiratory volumes. Effect of cigarette
smoking and respiratory symptoms. Am Rev Respir Dis
1988;138(4):837-49.
Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD,
Shaheen SO. Relation of birth weight and childhood
respiratory infection to adult lung function and death
from chronic obstructive airways disease. BMJ
1991;303(6804):671-5.
Shaheen SO, Barker DJ, Shiell AW, Crocker FJ, Wield
GA, Holgate ST. The relationship between pneumonia in
early childhood and impaired lung function in late adult
life. Am J Respir Crit Care Med 1994;149(3 Pt 1):616-9.
Prescott E, Lange P, Vestbo J. Socioeconomic status,
lung function and admission to hospital for COPD: results
from the Copenhagen City Heart Study. Eur Respir J
1999;13(5):1109-14.
34.
46.
33.
45.
32.
44.
31.
-D
30.
56.
24
65.
66.
67.
68.
69.
71.
72.
AL
T
ER
O
R
EP
R
O
D
O
80.
81.
82.
83.
PY
R
70.
79.
64.
78.
63.
77.
-D
62.
76.
IA
L
61.
75.
AT
ER
60.
74.
59.
73.
TE
D
58.
IG
H
57.
84.
85.
25
91.
92.
93.
O
D
EP
R
O
R
PY
R
98.
IG
H
97.
TE
D
96.
AT
ER
IA
L
95.
-D
94.
ER
90.
AL
T
89.
88.
99.
87.
86.
26
120.
121.
122.
124.
125.
AL
T
ER
O
R
EP
R
O
D
PY
R
123.
119.
-D
118.
IA
L
117.
AT
ER
116.
115.
TE
D
114.
IG
H
113.
27
AL
T
ER
O
R
EP
R
O
D
PY
R
IG
H
TE
D
AT
ER
IA
L
-D
28
AL
T
ER
O
R
EP
R
O
D
PY
R
IG
H
TE
D
AT
ER
IA
L
-D
29
AL
T
ER
O
R
EP
R
O
D
PY
R
IG
H
TE
D
AT
ER
IA
L
-D
30
AL
T
ER
O
R
EP
R
O
D
PY
R
IG
H
TE
D
AT
ER
IA
L
-D
31
AL
T
ER
O
R
EP
R
O
D
PY
R
IG
H
TE
D
AT
ER
IA
L
-D
248. Plant PK, Owen JL, Elliott MW. Early use of non-invasive
ventilation for acute exacerbations of chronic obstructive
pulmonary disease on general respiratory wards: a
multicentre randomised controlled trial. Lancet
2000;355(9219):1931-5.
249. Esteban A, Anzueto A, Alia I, Gordo F, Apezteguia C,
Palizas F, et al. How is mechanical ventilation employed
in the intensive care unit? An international utilization
review. Am J Respir Crit Care Med 2000;161(5):1450-8.
250. International Consensus Conferences in Intensive Care
Medicine: noninvasive positive pressure ventilation in
acute respiratory failure. Am J Respir Crit Care Med
2001;163(1):283-91.
251. Plant PK, Owen JL, Elliott MW. Non-invasive ventilation
in acute exacerbations of chronic obstructive pulmonary
disease: long term survival and predictors of in-hospital
outcome. Thorax 2001;56(9):708-12.
252. Conti G, Antonelli M, Navalesi P, Rocco M, Bufi M,
Spadetta G, et al. Noninvasive vs. conventional mechanical
ventilation in patients with chronic obstructive pulmonary
disease after failure of medical treatment in the ward: a
randomized trial. Intensive Care Med 2002;28(12):1701-7.
253. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L,
Stewart TE, et al. Characteristics and outcomes in adult
patients receiving mechanical ventilation: a 28-day
international study. JAMA 2002;287(3):345-55.
254. Esteban A, Frutos F, Tobin MJ, Alia I, Solsona JF, Valverdu I,
et al. A comparison of four methods of weaning patients
from mechanical ventilation. Spanish Lung Failure
Collaborative Group. N Engl J Med 1995;332(6):345-50.
255. Brochard L, Rauss A, Benito S, Conti G, Mancebo J,
Rekik N, et al. Comparison of three methods of gradual
withdrawal from ventilatory support during weaning from
mechanical ventilation. Am J Respir Crit Care Med
1994;150(4):896-903.
256. Hilbert G, Gruson D, Portel L, Gbikpi-Benissan G,
Cardinaud JP. Noninvasive pressure support ventilation
in COPD patients with postextubation hypercapnic
respiratory insufficiency. Eur Respir J 1998;11(6):1349-53.
257. Kessler R, Faller M, Fourgaut G, Mennecier B,
Weitzenblum E. Predictive factors of hospitalization for
acute exacerbation in a series of 64 patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care
Med 1999;159(1):158-64.
258. Mushlin AI, Black ER, Connolly CA, Buonaccorso KM,
Eberly SW. The necessary length of hospital stay for
chronic pulmonary disease. JAMA 1991;266(1):80-3.
259. Cotton MM, Bucknall CE, Dagg KD, Johnson MK,
MacGregor G, Stewart C, et al. Early discharge for
patients with exacerbations of chronic obstructive
pulmonary disease: a randomized controlled trial. Thorax
2000;55(11):902-6.
260. Hughes SL, Weaver FM, Giobbie-Hurder A, Manheim L,
Henderson W, Kubal JD, et al. Effectiveness of teammanaged home-based primary care: a randomized
multicenter trial. JAMA 2000;284(22):2877-85.
32
AL
T
ER
O
R
EP
R
O
D
PY
R
IG
H
TE
D
AT
ER
IA
L
-D
33
PY
R
IG
H
TE
D
AT
ER
IA
L
-D
AL
T
ER
O
R
EP
R
O
D
34
TE
D
IG
H
PY
R
IA
L
AT
ER
-D
T
N
AL
T
ER
O
R
EP
R
O
D
notes
35
36
TE
D
IG
H
PY
R
IA
L
AT
ER
-D
T
N
AL
T
ER
O
R
EP
R
O
D
PY
R
IG
H
TE
D
AT
ER
IA
L
-D
AL
T
ER
O
R
EP
R
O
D
The Global Initiative for Chronic Obstructive Lung Disease is supported by educational grants from: